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Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some
success, they do not speciﬁcally deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a
proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis.
In this paper we review the current body of literature regarding the use of this biological agent in the ﬁeld of transplantation.
Although limited experience with bortezomib may seem to show promise in the realm of transplant recipients desensitization
and treatment of AMR, there is also experience that may suggest otherwise. Bortezomib’s role in desensitization protocols and
treatment of AMR will be deﬁned better as more clinical data and trials become available.
1.Introduction
Kidney transplantation is the treatment of choice for most
patients with stage ﬁve chronic kidney disease (CKD). The
risk of death is less than half of that for dialysis patients
regardless of the immunosuppression protocol used [1].
Furthermore, most recipients acknowledge improved quality
of life. It is not surprising that the demand for donor kidneys
continually outpaces the supply. The United Network for
Organ Sharing (UNOS) has over 80,000 patients on the
kidney transplant waiting list, many of whom are highly
sensitized. Data obtained from the UNOS (2001−2008)
showed that the rates of transplantation for living donor
(LD) and deceased donor (DD) by panel reactive antibody
(PRA) status are less than 16% per year for patients with
PRAs of 10% to 80%, and less than 8% for patients with
PRAsmorethan80%.Thus,sensitizedpatientswithanylevel
of PRA are diﬃcult to transplant and have longer waiting
times on the transplant list [2]. Strategies for removing or
decreasing preformedantibodies in these patients are termed
desensitization. Literature review demonstrates 1-year allo-
graft survival between 69% and 96% for desensitizieted
patients [3].
The rejection risk for all patients in the ﬁrst year post
transplant is less than 12% based on the 2009 USRDS
database [4]. Highly sensitized transplant recipients, regard-
less of the desensitization protocol used, are at increased risk
for AMR. Both desensitization and AMR are managed with
thesimilartherapeuticarsenal;howeverprotocolsarecenter-
speciﬁc and there are no consensus guidelines [5]. The two
desensitization protocols for which clinical eﬃcacy has been
demonstrated are high-dose IVIG or low-dose IVIG with
either plasmapheresis (PP) or immunoadsorption [6, 7].
Additionally, some transplant centers may add intravenous
steroids,rabbitantithymocyteglobulin(rATG),orrituximab
[8]. As mentioned above, these modalities are variably
eﬀective in decreasing reactive antibody levels [9–11].
Thereisconcernthattheroleofplasmacellsinmediating
humoral rejection is not adequately addressed [9]. Since
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Figure 1: A simpliﬁed, conceptual diagram of the targets of current therapeutic modalities for pre-transplant desensitization and treatment
of antibody mediated rejection. The dashed arrows indicate the sites of action for the therapeutics. Rituximab exerts its eﬀects on CD20+
B-cell lines with absence of activity against pro-B cells and plasma cells and questionable activity against memory B cells. Bortezomib targets
plasma cells which elaborate the antibodies implicated in donor-speciﬁc antibodies and antibody-mediated rejection while the antibodies
produced are targeted with intravenous immunoglobulin (IVIG) and plasmapheresis (PP).
by rituximab’s ability to deplete CD20 positive B-cell line
members as detailed in (Figure 1). There is one variant of
AMR in which over 30% of inﬁltrating cells are mature
plasma cells, and once diagnosed graft survival is generally
less than one year post diagnosis [12]. Hence, it is of
importance to target this cell lineage in desensitization and
AMR treatment strategies.
Reservations were expressed in the literature that plasma
cells were unaﬀected by current desensitization protocols.
The study by Ramos et al. conﬁrmed these ruminations.
The group conducted a study where the spleens of patients
receiving desensitization were histologically compared to
control spleens for their levels of diﬀerent B-cell line
members [13]. The study showed that levels of na¨ ıve B
cells (CD20+ and CD79+), memory B cells (CD27+), and
plasma cells (CD138+) in the spleens of patients desensitized
with PP and low-dose IVIG did not diﬀer signiﬁcantly from
control spleens. It was also noted that despite the addition
of rituximab to the PP and IVIG protocol, the amount of
memory B cells and plasma cells were still comparable to
controls. Combination therapy in the study (PP, low-dose
IVIG, rituximab, and rATG) did show a small reduction of
memory B cells, but plasma cell levels were still on par with
controls. This study conﬁrmed the reservations expressed in
the literature that plasma cells were unaﬀected by current
desensitization protocols [9, 13].
Bortezomib (Velcade, Millennium Pharmaceuticals,
Cambridge, MA) depletes plasma cells via proteasome
inhibition [8]. In 2008, investigators at the University of
Cincinnati published their experience of six patients with
AMR and donor-speciﬁc antibodies (DSA) elevation post
transplantation who had reversal of AMR with a single
cycle of bortezomib [14]. Several other transplant centers
have since utilized bortezomib for treatment of AMR with
varying success [14–20]. Herein, we review the current body
of literature regarding using bortezomib in pretransplant
desensitization and treatment of AMR.
2. Bortezomib Biological Effect
Bortezomib was ﬁrst synthesized in 1995. After just seven
years, the Food and Drug Administration (FDA) approved
this drug as treatment for multiple myeloma, a plasma cell
dyscrasia, which remains its only approved indication. A
phase 3 multicenter trial published in the New England Jour-
nal of Medicine in 2008 demonstrated marked improvement
in outcomes for newly diagnosed myeloma patients who
received bortezomib in addition to the treatment standard
of melphalan and prednisone. This 682-patient randomized
trial demonstrated the superiority, along with safety and
eﬃcacy of Bortezomib. Now this drug is ﬁrst-line treatment
in patients with newly diagnosed myeloma who cannot
receive immediate autologous stem cell transplantation [21].
The drug has been used oﬀ label in the transplant setting
since 2005 both to reduce DSAs in highly sensitized patients
and as an adjunct therapy for AMR.
Bortezomib (C19H25BN4O4) has a central boron atom
whichbindsthecatalyticsiteofthe26Sproteasomewithhigh
aﬃnity and speciﬁcity. Present in all cells, the proteasome
degrades ubiquitinylated, abnormal, and misfolded proteins;
thus regulating protein expression and function [22]. Simply
put, proteasome inhibition during mitosis inhibits the
degradation of cell-cycle regulatory proteins resulting in
cell-cycle death via apoptosis. One such regulatory protein
is NFkB, which has an important role in controlling cell
cycle progression, loading of Class I MHC molecules, cellJournal of Transplantation 3
adhesion, and activation of cytokines [23]. This molecule is
inhibited by transcription factor IkB. Bortezomib’s interfer-
ence with these two molecules leads to the accumulation and
aggregation of unfolded proteins and eventual plasma cell
apoptosis.
Both in vitro and in vivo (murine and human) studies
have noted that this drug has a propensity to cause apoptosis
of CD138+ plasma cells [16, 24]. Bortezomib also exerts
numerous indirect eﬀects on circulating B cells and TH cells;
for example, it may lead to blockade of T-cell cycling leading
to apoptosis of TH cells and reduction of bone marrow
interleukin-6 can decrease B-cells numbers [21].
3. Bortezomib Pharmacokinetics,
Pharmacodynamics, andSide Effects
The pharmacokinetics of bortezomib can be characterized
by rapid and wide distribution, a prolonged elimination
half life, and hepatic cytochrome P-450 (CYP) isoenzyme
metabolism [25]. After a rapid distribution half life of
approximately 10 minutes, peak plasma bortezomib concen-
trations range 60 to 120ng/mL following repeated doses of
1t o1 . 3m g / m 2. Total body clearance decreases from 102 to
112L/h after the ﬁrst dose and from 15 to 32L/h following
repeated doses [26]. Subsequent elimination half-life ranges
from 40 to 190 hours. A high volume of distribution (500 to
1800L/m2) in patients with multiple myeloma is suggestive
ofextensivedistributiontoperipheraltissues.Invitrostudies
indicate bortezomib metabolism to occur primarily via
hepatic oxidation by CYP3A4, CYP2C19, CPY1A2, and to
a lesser extent CYP2D6 and CYP2C9, to inactive metabo-
lites. While inhibitors and inducers of these isoenzymes
are commonly seen especially in organ transplant popu-
lations, clinically signiﬁcant interactions with bortezomib
and enzyme inducers have not been reported. Concomitant
administration of ketoconazole has been shown to increase
systemic bortezomib exposure by 35% with correspond-
ing increased proteasome inhibitory activity, although side
eﬀects were similar to those not receiving ketoconazole
[27]. On the other hand, ascorbic acid (Vitamin C) has
been shown to interfere with bortezomib’s proteasome
inhibitory activity through alternative mechanisms [28]. The
pharmacodynamic proﬁle of bortezomib provided a basis
for its current recommended dosing regimen. Following
intravenous administration, maximum percent inhibition
of 20S proteasome is observed after 5 minutes, reaching
am e a no f7 0 −84% inhibition [26]. With decreases in
drug concentration, 20S proteasome inhibition is reversed
with mean inhibition declining to 22−48% at 48 hours
and returning to baseline at 72 hours post administration.
Pharmacodynamic properties were similar between 1.0 and
1.3mg/m2 dose regimens [26]. Adverse eﬀects are reported
in Phase II and Phase III studies from multiple myeloma
and mantle cell lymphoma populations. The main adverse
eﬀect of this drug is neurotoxicity which manifests as a
dose-related peripheral sensory neuropathy that may occur
in about 30% of treated patients. This neuropathy can
often be severe but is reversible with discontinuation of
the drug. Severe events (National Cancer Institute Common
Toxicity Criteria grade 3 event) also noted with bortezomib
therapy include thrombocytopenia (28%) and neutropenia
(11%) which are usually managed with standard approaches.
Thrombocytopenia due to bortezomib has been observed to
occur in patients primarily with low baseline platelet levels
and resolves upon drug discontinuation. Other commonly
reported side eﬀects include nausea (55%), diarrhea (44%),
and fatigue (12%); the gastrointestinal disturbances are
usually mild and managed easily with standard approaches
[29]. In the largest series of kidney transplant recipients
to date, Walsh et al. report a similar pattern of adverse
eﬀects, including low-grade gastrointestinal side eﬀects, mild
to moderate anemia, neutropenia, and thrombocytopenia,
andprimarilymildcasesofperipheralneuropathyinpatients
undergoing treatment for desensitization and humoral rejec-
tion [30].
Dosing of bortezomib is similar regardless of the route
of application, it does not require renal or hepatic dosing
adjustments, and the drug is no longer detectable within 30
minutes of injection [22].
4. Bortezomib Use inKidney Transplantation
To our knowledge, this drug has never consistently been
used in nonkidney transplant protocols. There are several
published case reports and case series detailing bortezomib’s
application in kidney transplantation. Many centers now use
velcade-based protocols for highly sensitized patients.
4.1. Bortezomib in Desensitization Protocols. Table 1 lists the
published data of this drug’s use in kidney transplantation.
The ﬁrst published data is from University of Cincinnati
by Idica et al. [17] in 2008. Thirteen highly sensitized
patients received this drug and all had reduction in the
normalized mean ﬂuorescent units (MFI) of the donor-
speciﬁc antibodies; ten of whom (77%) had signiﬁcant
decrease in DSA.
Trivedi et al. reported on 11 patients with a post-
transplant anti-HLA antibody titer greater than 1000MFI,
but without acute rejection. The use of bortezomib with
plasmapheresis was successful in decreasing antibody levels
to under 1000MFI within a median time of 24 days from
treatment initiation in all but two patients [15]. Both of
these two patients had a peak MFI greater than 10,000.
Overall the study suggests that bortezomib can be used to
decrease DSA levels with minimal toxicity [15]. Four of 11
patients had reappearance of anti-HLA antibodies despite
initial eﬀective reduction with one cycle of bortezomib. The
authors suggested that certain patients may need more than
one cycle of treatment to decrease DSA levels. With clinically
stable patients, the study’s ﬁndings neither argues for nor
against bortezomib’s ability to aﬀect the clinical course of
graft rejection, but the study does point to the possible role
that bortezomib can play in decreasing DSA levels that are
implicated in AMR.
In the case series by Wahrmann et al., the group used
two cycles of bortezomib for pre-transplant desensitization
for two highly sensitized kidney recipients [18]. The ﬁrst
cycle of bortezomib was given alone followed by a cycle of4 Journal of Transplantation
Table 1: Clinical characteristics and outcomes of published desensitization/rejection protocols using Bortezomib as combination or solo
therapy.
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(i) 2 cycles bortezomib at
intervals of 3- and
4-months, both given with
steroids
(i) cPRA mildly decreased in both
patients
(ii) Overall, no signiﬁcant eﬀect on the












(iii) pheresis done at least
72 hours post-bortezomib
(i) Immediate signiﬁcant reduction of
DSA
(ii) Good allograft function at 5- and
6-months follow-up
(iii) One patient had re-elevation of




et al. 2010 [20] Paris, France 4 AMR4 (i) 1 cycle bortezomib (solo
therapy)
(i) No eﬀect on anti-HLA antibodies








(i) 4 cycles bortezomib, one
dose rituximab, daily
mycophenolate
(i) Reduced PRA (55% → 30%) and
signiﬁcant reduction of class I
antibodies
(ii) Successful transplant with good
allograft function at 6-months
+
Everly 2009 [14] Cincinnati
Ohio, USA
5 AMR
(i) 1 cycle bortezomib post
treatment with “other”
antihumoral therapies
(i) Median follow-up of 6.9 months.
All patients had 50% reduction of DSA
in 2-4 weeks.











(i) 1 cycle bortezomib
followed by 2-4 treatments
plasmapheresis and steroids
(ii) 6 of 11 patients received
one dose rituximab
(i) Follow-up at least 80 days post
treatment. All patients had reduction
in MFI within 4 weeks.
(ii) 7 of 11 patients had reappearance
of anti-HLA antibodies
+/−




2 AMR (i) 1 cycle bortezomib, daily
plasmapheresis and IVIG
(i) Resolution of Rejection Peak MFI
13k and 14k2 At 1-year follow-up: MFI
zero at and serum creatinine 0.6 and
1.3mg/dl
+
Idica et al. 2008
[17] ?? 13 DS (i) Details not apparent
from article
(i) 10 of 13 had signiﬁcant decrease
(reversal) of DSA
(ii) 100% had reduced MFI of
antibodies
+
1DS: Desensitization, AMR = Antibody Mediated Rejection, DSA: Donor Speciﬁc Antibodies (elevated antibodies, but no clinical rejection). 2MFI: Mean
Fluorescence Index. 3Side eﬀects mentioned include thrombocytopenia and gastrointestinal toxicities. 4Patients had subclinical antibody mediated injuries
with persistent DSA; hence it was acceptable to use bortezomib as solo therapy.
bortezomib with dexamethasone as dexamethasone has been
shown to enhance treatment eﬃcacy in multiple myeloma
patients. In the two patients, PRA decreased from 87% to
80% in patient 1 and 37% to 13% in patient 2. Despite
the mild decrease in PRA levels, bortezomib therapy led to
more than 50% decrease in the levels of anti-HLA antibodies
triggering C4d deposition on single antigen Luminex beads
asmeasuredinMFIafter6monthsoffollowup.Thissuggests
that bortezomib may have a role in decreasing complement
ﬁxation especially as C4d is one of the histological markers
leading to the diagnosis of AMR [18]. Yet, bortezomib’s mild
eﬀect on PRA for pre-transplant desensitization may suggest
the need for adjunct modalities that target antibodies such as
PP and IVIG as well as further exploration of bortezomib in
transplant desensitization.
4.2.BortezomibinRejectionProtocols. Intheﬁrststudytouse
bortezomib as an antirejection modality, 6 kidney transplant
recipients with AMR and acute cellular rejection (ACR)
refractory to plasmapheresis, IVIG, and/or rATG, and/or
rituximab were treated with bortezomib [14]. Bortezomib
therapy led to prompt rejection reversal (within days to
weeks) and in all the cases, there was improved renal
function and reduction in DSA levels. Recurrent rejection
episodes in 2 patients were suppressed for up to 5 months;
furthermore, the anti-HLA antibody with the highest levelsJournal of Transplantation 5
(immunodominant DSA) were decreased by more than 50%
within 14 days and remained suppressed for up to 5 months
[14]. As the ﬁrst positive study of incorporating bortezomib
as a suppressor of DSA in the treatment of AMR, others
groups have emulated this strategy.
Perry et al. analyzed the eﬀects of rATG, IVIG, rituximab,
and bortezomib on enriched populations of bone marrow
derived plasma cells and indicated that only bortezomib was
successful in causing plasma cell apoptosis and completely
blocking anti-HLA IgG secretion against all speciﬁcities in
vitro compared to controls [16]. In comparing the bone
marrow of 2 positive cross-match kidney recipients at the
time of AMR and at 1 week after treatment with bortezomib
for AMR, in vivo data showed a decrease in the percentage of
bonemarrowplasmacells,adecreaseinantibodyproduction
(including DSA), and a decrease in the number of plasma
cell allospeciﬁcities in the bone marrow aspirates obtained
after bortezomib treatment. With resolution of AMR and
normalkidneyfunctionatoneyearposttransplant,thestudy
suggests that bortezomib can target plasma cells implicated
in AMR [16].
In the study by Walsh et al., two patients undergoing
acute AMR with high DSA and positive Cd4 staining on
biopsy two weeks after kidney transplantation were treated
with a multiday regimen consisting of PP paired with
methylprednisolone and bortezomib along with a single
dose of rituximab [19]. The theoretical rationale behind
this protocol was that bortezomib would target plasma
cells, rituximab would target plasma cell production from
the pool of memory B-cells, and plasmapheresis would
remove antibody levels creating a demand for increased
antibody production to potentiate the eﬀect of bortezomib’s
proteasome inhibition. In addition, plasmapheresis was
used to remove pre-existing antibodies that may have been
circulating for weeks and thus measure antibody levels
that would correlate with the magnitude of the antibody
producing plasma cell population. By nearly 14 days after
treatment, DSA levels had dropped signiﬁcantly as well
as repeat biopsy showed faint peritubular capillary C4d
labeling and decreased glomerular C4d deposition. For
patient 1, DSA remained below detectable thresholds for 6
months following bortezomib treatment. For patient 2, DSA
remained below detectable thresholds for 2 months before
a rebound in DSA titers were observed. A repeat cycle of
PP, rituximab, and bortezomib treatment was given showing
undetectable DSA within the ﬁrst week of retreatment [19].
The group concluded that bortezomib-based regimens may
be beneﬁcial in rapid DSA elimination in the setting of acute
AMR as an adjunct to commonly used modalities such as PP.
In the study by Sberro-Soussan et al., the group came
to an opposite conclusion of bortezomib eﬃcacy in four
patients at least 1 year out from renal transplantation
[20]. In these four patients experiencing subacute AMR, no
signiﬁcant decrease in DSA intensity as measured by MFI
occurred despite use of PP, IVIG, rituximab, and bortezomib
in 150 days of followup. In addition, bortezomib’s activity
on long-lived plasma cells as measured by observing any
decrease in antiviral antibodies (antihepatitis B surface
antigen) and total IgG was not demonstrated as neither
decreased signiﬁcantly with a cycle of bortezomib. The
group postulated that lack of activity against DSA may have
been secondary to a long period of DSA stability following
transplant as bortezomib was administered nearly 1 year or
more after transplantation of these patients. They concluded
that a single cycle of bortezomib does not seem to exert
an eﬀect on any long-lived antibody levels (further than
1 year post-transplant) whether the long-lived antibodies
be DSA in sensitized kidney transplant recipients, anti-viral
antibodies, or total immunoglobulins [20]. Yet, the group
postulated that bortezomib may be more eﬀective in more
short-lived, intensely producing plasma cells as previously
noted in the literature. Finally, as this is the only study to use
bortezomib as solo immunotherapy, steroids may be critical
for a synergistic, proapoptotic eﬀect in normal plasma cells.
5. Conclusions
Bortezomib’s ability to target antibody producing plasma
cell has generated interest in its use for pre-transplant
desensitization and treatment of AMR. This drug may
provide a promising insight into the management of patients
undergoing kidney transplantation especially considering
the large numbers of highly sensitized patients on the kidney
transplant waiting list. New therapeutic strategies targeting
reduction in DSA as well as managing AMR can provide
opportunitiesforthesepatients.Althoughlimitedexperience
with bortezomib may seem to show promise in the realm
of transplant recipients desensitization and treatment of
AMR, there is also experience that may suggest otherwise.
Speciﬁcally, the use of bortezomib with other accepted
modalitiesfordesensitization(PP,IVIG,andrituximab)may
make it diﬃcult to tease out bortezomib’s role in transplant
desensitization and treatment of AMR as highlighted in
the limited reported instances of its use. Bortezomib’s role
in transplant desensitization may be better elucidated as
more clinical data and well-designed clinical trials become
available.
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